No broadly effective vaccines are available for prevention of group B meningococcal
disease, which accounts for> 50% of all cases. The group B capsule is an autoantigen and …

Neisseria meningitidis is a Gram-negative microorganism that exists exclusively in humans
and can cause devastating invasive disease. Although capsular polysaccharide-based …

Complement forms an important arm of innate immunity against invasive meningococcal
infections. Binding of the alternative complement pathway inhibitor factor H (fH) to fH-binding …

Serogroup B meningococcal (MenB) disease remains a serious public health problem for
which a cross-protective vaccine effective against a wide range of MenB isolates has not …

Vaccines have had a major impact on the reduction of many diseases globally. Vaccines
targeted against invasive meningococcal disease (IMD) due to serogroups A, C, W, and Y …

The dominant clinical features of meningococcal disease are fever, rash, and meningitis, but
the initial signs and symptoms are often nonspecific and therefore may be indistinguishable …

Neisseria meningitidis is responsible for two major diseases: cerebrospinal meningitis
and/or septicemia. The latter can lead to a purpura fulminans, an often-fatal condition owing …

Neisseria meningitidis is a leading cause of meningitis and sepsis worldwide. The first broad-
spectrum multicomponent vaccine against serogroup B meningococcus (MenB), 4CMenB …

Lyme disease (LD) is an emerging zoonotic infection that is increasing in incidence in North
America, Europe, and Asia. With the development of safe and efficacious vaccines, LD can …

Introduction Neisseria meningitidis causes epidemics of meningitis in sub-Saharan Africa.
These have mainly been caused by capsular group A strains, but W and X strains are …